Kura Oncology
Pitch Summary: Kura Oncology is positioned as a strong buy due to the potential of its drug Ziftomenib (Komzifti) to capture significant market share in the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The drug’s differentiation from competitors, particularly Syndax’s Revuforj, is highlighted by its lower cardiac risk profile, which could enable Kura to […]
